KLOW 80 mg – GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg

$125.00

KLOW is a research blend containing GHK-Cu, BPC-157, TB-500 and KPV. The blend itself has no published human clinical trials, and evidence for individual ingredients does not establish benefits of the combination. Research use only; not for human or animal consumption.

RESEARCH USE ONLY Laboratory research
BATCH DOCUMENTATION Not currently available
PRODUCT FORMAT 10 mg Ā· Lyophilized powder

For laboratory research only. Not for human or animal consumption.

Category:

VIP Peptides Ā· Research Blend

KLOW Research Profile

KLOW is a multi-ingredient research blend containing GHK-Cu,
BPC-157, TB-500 and KPV. There are no published human clinical
trials of the KLOW blend itself. Research on its ingredients
individually does not establish benefits of the combination.

4 Components
GHK-Cu, BPC-157, TB-500 and KPV 10mg
Research Blend
Combination evidence is limited
80 mg
Common total vial quantity; verify label
Research Use Only
Not for consumption

Product Information

About KLOW

KLOW is a marketplace name for a blend of four peptides:
GHK-Cu, BPC-157, TB-500 and KPV 10mg. It is sometimes described as
a version of the GLOW blend with KPV added.

Product ratios can vary between suppliers. Some products are
advertised as an 80 mg total vial with GHK-Cu as the largest
component, but the exact amounts should be confirmed against
the specific product label and batch documentation.

ā€œTB-500ā€ is commonly used as a product name for a thymosin beta-4
fragment. Verify the identity and sequence against product-specific
documentation; evidence for one peptide or fragment should not
automatically be applied to another.

Product Specifications

Product KLOW
Components GHK-Cu, BPC-157, TB-500 and KPV
Total vial quantity Commonly listed as 80 mg; verify product label
Component ratios Supplier- and product-specific
Blend research No published human clinical trials of KLOW itself
Product documentation Check the matching batch report, if available
Use classification Research use only

Research Areas

What Research Has Examined


GHK-Cu Research

GHK-Cu has been studied in relation to copper binding, extracellular
matrix and collagen pathways, antioxidant activity, and skin or
wound research. Human evidence is stronger for topical applications
than for injectable use.


BPC-157 & TB-500 Research

Preclinical research has examined BPC-157 and thymosin beta-4
related peptides in tissue and cellular pathways. Human evidence
for BPC-157 is limited, and FDA has not identified human exposure
data for drug products containing the TB-500 fragment.


KPV Research

KPV, a tripeptide fragment of alpha-MSH, has been examined in
laboratory and preclinical research involving inflammatory
signaling and intestinal epithelial pathways. These findings
do not establish a clinical effect in people.

Evidence Overview

Blend-Specific Evidence Is Missing

The proposed rationale for KLOW is based on research on its
individual components. No published human clinical trials establish
the safety, effectiveness or ā€œsynergisticā€ effect of the specific
four-component blend.

Animal or laboratory findings for an individual ingredient cannot
confirm a benefit from the complete blend. Results may also depend
on ingredient identity, ratio, product quality and formulation.

Safety & Regulatory Status

Important Product Limitations

KLOW is not an FDA-approved drug or established medical treatment.
FDA safety materials describe limited human safety information and
potential immunogenicity concerns involving aggregation or
peptide-related impurities for injectable products containing
BPC-157, TB-500 or GHK-Cu. FDA has also noted that human exposure
data for drug products containing the TB-500 fragment have not
been identified.

Product ratios and quality may vary. A total vial quantity does not
verify the amount or identity of each component. A third-party
certificate of analysis, if available, should match the specific
batch; its presence alone does not establish that a product is safe
or suitable for human use.

BPC-157 and TB-500 are included in WADA’s 2026 Prohibited List.
Athletes are responsible for checking the current rules that apply
to their sport and organization.

For laboratory research only. Not intended for human or animal
consumption, injection, clinical use, diagnosis, treatment, cure,
mitigation or prevention of disease.

Reviews

There are no reviews yet.

Be the first to review “KLOW 80 mg – GHK-Cu 50 mg / BPC-157 10 mg / TB-500 10 mg / KPV 10 mg”

Your email address will not be published. Required fields are marked *

Scroll to Top